Every material Form 8-K CME has filed with the SEC since October 23, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CME Group reported third-quarter 2026 results on October 21, 2026, with revenue of $1.7 billion, up from $1.5 billion a year earlier, and diluted earnings per share of $2.89, up from $2.49. Adjusted diluted EPS was $3.02 versus $2.68 a year earlier, and the company returned nearly $1 billion to shareholders during the quarter.
Q3 2026 total revenues of $1,737.3 million versus $1,537.6 million in Q3 2025
Diluted EPS of $2.89 versus $2.49; adjusted diluted EPS of $3.02 versus $2.68
Average daily volume of 29.4 million contracts, a third-quarter record
Returned nearly $1 billion to shareholders: $465 million in dividends and $524 million in share repurchases
CME Group announced senior leadership changes in its finance and legal divisions. Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer. The changes also bring a new General Counsel, John Marchese, and a new Chief Accounting Officer, Matthew Render, but the filing gives no financial results or figures tied to these appointments.
Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer.
Matthew Render succeeds Tobin as Managing Director, Chief Accounting Officer effective November 2, 2026, after joining CME Group in August 2026.
John Marchese is promoted to General Counsel, succeeding Jonathan Marcus, who has served as General Counsel since 2022 and is stepping down later this month.
Tobin previously planned to retire effective October 30, 2026, but will now continue with the company.
CME Group reported second-quarter 2026 results for the quarter ended June 30, 2026. Total revenue rose to $1.7 billion from $1.69 billion a year earlier, and diluted earnings per share were $2.88 versus $2.81, but GAAP operating income fell to $1.1 billion from $1.13 billion.
Total revenue was $1,706.2 million, up from $1,692.0 million in Q2 2025; clearing and transaction fees were $1,352.5 million.
Diluted EPS was $2.88 versus $2.81; adjusted diluted EPS was $2.99 versus $2.96.
Operating income was $1,107.1 million versus $1,129.3 million; adjusted operating income was $1,185.0 million versus $1,200.8 million.
As of June 30, 2026, cash was $2.3 billion and debt was $3.4 billion; the company repurchased $695 million of its common shares and paid about $468 million in dividends in the quarter.
CME Group said Chairman and CEO Terry Duffy will become Executive Chairman, and President and CFO Lynne Fitzpatrick will succeed him as CEO. The change takes effect on the later of March 1, 2027 and the date the company files its 2026 Form 10-K. The company will also search for a new CFO to succeed Fitzpatrick.
Transition effective on the later of March 1, 2027 and the filing date of the 2026 Form 10-K; Board approved it June 16, 2026
Duffy serves as Executive Chairman from the Transition Date through December 31, 2027
Fitzpatrick's agreement sets a $1.2 million annual base salary, a bonus opportunity of 200% of salary and a long-term incentive opportunity of 700% of salary
Fitzpatrick's severance includes a lump sum of two times annual base salary and 18 months of Company-paid healthcare coverage
CME's clearing unit, Chicago Mercantile Exchange Inc., amended its 364-day secured credit facility, effective April 22, 2026, as Amendment No. 11. The facility provides temporary liquidity for clearing-related disruptions and is eligible to be increased to $10 billion. The filing describes it as a routine backstop for the clearing house and does not report a financial result or a change in shareholder economics.
Amendment No. 11 to the 364-day multi-currency credit facility effective April 22, 2026
Facility is $7 billion revolving secured credit, eligible to be increased to $10 billion
Bank of America, N.A. is Administrative Agent; Citibank, N.A. is Collateral Agent and Collateral Monitoring Agent
CME must remain in compliance with a consolidated tangible net worth test
CME Group reported first-quarter 2026 results on April 22, 2026, with revenue of $1.9 billion, up 14% from a year earlier, and net income of $1.2 billion. Diluted earnings per share were $3.18, compared with $2.62 in the first quarter of 2025, and adjusted diluted earnings per share were $3.36, compared with $2.80. The filing does not include updated full-year guidance.
Average daily volume reached 36.2 million contracts, up 22% from the first quarter of 2025.
Diluted EPS was $3.18 versus $2.62 a year earlier; adjusted diluted EPS was $3.36 versus $2.80.
Operating income was $1.3 billion, compared with $1.1 billion in the first quarter of 2025.
The company paid about $2.7 billion in dividends and repurchased $536 million of common shares in the quarter.
On February 4, 2026, CME Group reported fourth-quarter and full-year 2025 results, with full-year revenue of $6.5 billion and operating income of $4.2 billion. Full-year GAAP diluted earnings per share were $11.16, up from $9.67 in 2024, and the company said it was the fourth consecutive year of record annual revenue and adjusted earnings per share.
Fourth-quarter 2025 revenue was $1.6 billion, compared with $1.5 billion in the fourth quarter of 2024.
Fourth-quarter 2025 GAAP diluted EPS was $3.24 versus $2.40; adjusted diluted EPS was $2.77 versus $2.52.
Full-year 2025 adjusted diluted EPS was $11.20 versus $10.26 in 2024.
Record 2025 average daily volume of 28.1 million contracts; Q4 ADV was 27.4 million contracts, up 7% from Q4 2024.
CME Group reported third-quarter 2025 results, with total revenue of $1,537.6 million, down from $1,584.4 million a year earlier, and net income of $908.0 million, down from $912.8 million. Diluted earnings per share were $2.49 versus $2.50, while adjusted diluted EPS was $2.68, flat with the prior year. The headline GAAP measures declined year over year, which matters to shareholders because lower trading activity reduced revenue.
Total revenue was $1,537.6 million for the quarter ended September 30, 2025, versus $1,584.4 million in the same quarter of 2024.
Diluted EPS was $2.49 on a GAAP basis versus $2.50 a year earlier; adjusted diluted EPS was $2.68, unchanged from the prior year.
Market data and information services revenue was a record $203 million; clearing and transaction fees were $1.2 billion.
Quarterly average daily volume was 25,322 thousand contracts, down from 28,289 thousand in the third quarter of 2024.
CME Group said its Chief Accounting Officer, Jack Tobin, has decided to retire after more than 23 years with the company and seven...
Jack Tobin notified CME Group of his retirement decision on September 9, 2025.
Tobin will remain Chief Accounting Officer until October 30, 2026.
Tobin has held the role since 2015; the company says the departure is voluntary and not due to any disagreement on accounting, operations, policies or practices.
CME Group will search for a successor, and Tobin will work with that person on the transition.
CME Group reported second-quarter 2025 revenue of $1.7 billion, up 10% from the same quarter in 2024, and record average daily volume of 30.2 million contracts, up 16%. Diluted earnings per share were $2.81 on a GAAP basis, compared with $2.42 a year earlier, and $2.96 on an adjusted basis, compared with $2.56.
Q2 2025 revenue of $1.7 billion versus $1.5 billion in Q2 2024; operating income of $1.1 billion
Diluted EPS of $2.81 (GAAP) versus $2.42; adjusted diluted EPS of $2.96 versus $2.56
Average daily volume of 30.2 million contracts, up 16%; Micros ADV of 4.1 million contracts
As of June 30, 2025: $2.2 billion in cash and $3.4 billion of debt; about $3.0 billion in dividends paid in the first six months
CME Group entered a new multi-currency revolving credit facility of $2.25 billion, which can be increased to $3.25 billion, maturing April 23, 2030. The company also amended its 364-day secured credit facility for its clearing house, set at $7 billion and eligible to rise to $10 billion, to provide temporary liquidity in specified scenarios. The filing describes the facilities as standard backup and working capital arrangements, and it does not disclose any drawn balances.
New senior revolving credit facility of $2.25 billion, expandable to $3.25 billion, effective April 23, 2025
Facility matures April 23, 2030 and can be prepaid without premium or penalty; proceeds are for working capital and general corporate purposes
Amendment No. 10 to the 364-day clearing house credit facility sets a $7 billion secured facility, eligible to rise to $10 billion
Both agreements require maintenance of minimum net worth or consolidated tangible net worth tests
CME Group reported first-quarter 2025 results, with revenue of $1.6 billion, up 10% from a year earlier, and GAAP diluted earnings per share of $2.62 versus $2.35. Adjusted diluted EPS was $2.80 versus $2.50, and average daily volume reached a record 29.8 million contracts. The release does not include updated forward guidance.
Total revenues of $1,642.3 million for the quarter ended March 31, 2025, up 10% from the prior year
GAAP net income of $956.2 million versus $855.2 million; diluted EPS $2.62 versus $2.35
Adjusted diluted EPS of $2.80 versus $2.50 in the first quarter of 2024
Average daily volume of 29.8 million contracts; cash of $1.6 billion and long-term debt of $3.4 billion at March 31, 2025
CME Group completed a $750 million offering of 4.400% notes due 2030 on March 10, 2025, under its shelf registration. The company plans to use the net proceeds, with cash on hand, to retire its $750 million of 3.00% notes due 2025 and for general corporate purposes. The deal refinances existing debt and adds new debt, with interest payable each March 15 and September 15 beginning September 15, 2025.
Notes: $750 million aggregate principal, 4.400%, due 2030, offered at 99.573% of principal
Proceeds plus cash on hand intended to retire all $750 million of 3.00% notes due 2025
Interest payable March 15 and September 15, starting September 15, 2025; change of control repurchase at 101% of principal
CME Group reported fourth-quarter 2024 revenue of $1.5 billion, up from $1.4 billion a year earlier, with diluted earnings per share of $2.40 versus $2.24. For full-year 2024, revenue was $6.1 billion and diluted earnings per share were $9.67, compared with $8.86 in 2023. On February 6, 2025, the company also declared a first-quarter dividend of $1.25 per share, up 9% from $1.15.
Q4 2024 net income was $875 million, up from $815 million in Q4 2023; diluted EPS was $2.40 versus $2.24.
Q4 2024 adjusted diluted EPS was $2.52, a non-GAAP measure reconciled to GAAP in the release.
Full-year 2024 revenue was $6.1 billion and net income was $3.5 billion.
First-quarter 2025 dividend of $1.25 per share, a 9% increase from $1.15.
CME Group's board approved an amended employment agreement extending Chairman and CEO Terry Duffy's term through December 31, 2026, with base salary, target bonus and long-term incentive targets unchanged. The company also named CFO Lynne Fitzpatrick President and CFO, and COO Julie Holzrichter is stepping down to become an advisor, with Suzanne Sprague succeeding her as COO. The filing reports no financial results, so the changes affect shareholders mainly through leadership continuity and the terms of executive compensation.
Duffy's employment term extended to December 31, 2026; the agreement may be extended further to December 31, 2027
Lynne Fitzpatrick promoted to President and Chief Financial Officer; she has served as CFO since April 2023
Julie Holzrichter, COO since 2014, steps down and will remain with the company as an advisor
Suzanne Sprague, Senior Managing Director and Global Head of Clearing and Post-Trade Services, assumes the COO role
CME Group reported record third-quarter 2024 revenue of $1.6 billion, up from $1.3 billion a year earlier, with net income of $913 million and diluted earnings per share of $2.50, compared with $2.06 in the third quarter of 2023. The company said the quarter was its best in history, with record average daily volume of 28.3 million contracts, and it also reported non-GAAP adjusted diluted EPS of $2.68.
Q3 2024 revenue $1.6 billion (total revenues $1,584.4 million); operating income $1,024.2 million
Diluted EPS $2.50 vs $2.06 a year earlier; adjusted diluted EPS $2.68 vs $2.25
Record quarterly ADV of 28.3 million contracts; clearing and transaction fees revenue $1.3 billion
Approximately $419 million paid in dividends during the quarter; about $2.6 billion in cash and $3.4 billion of debt as of September 30, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CME filing is on SEC EDGAR ↗. 8-K briefs of other companies →